Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales Market Report 2019 by Manufacturer, Region, Type and Application

Table of Contents

1 Report Overview

• 1.1 Definition and Specification
• 1.2 Report Overview
  • 1.2.1 Manufacturers Overview
  • 1.2.2 Regions Overview
  • 1.2.3 Type Overview
  • 1.2.4 Application Overview
• 1.3 Industrial Chain
  • 1.3.1 Squamous Non-Small Cell Lung Cancer Therapeutics Overall Industrial Chain
  • 1.3.2 Upstream
  • 1.3.3 Downstream
• 1.4 Industry Situation
  • 1.4.1 Industrial Policy
  • 1.4.2 Product Preference
  • 1.4.3 Economic/Political Environment
• 1.5 SWOT Analysis

2 Market Analysis by Types

• 2.1 Overall Market Performance(Volume)
  • 2.1.1 BMS-906024
  • 2.1.2 Buparlisib Hydrochloride
  • 2.1.3 FP-1039
  • 2.1.4 Ipilimumab
  • 2.1.5 JNJ-42756493
  • 2.1.6 Lenvatinib
  • 2.1.7 Others
• 2.2 Overall Market Performance(Value)
  • 2.2.1 BMS-906024
  • 2.2.2 Buparlisib Hydrochloride
  • 2.2.3 FP-1039
  • 2.2.4 Ipilimumab
  • 2.2.5 JNJ-42756493
  • 2.2.6 Lenvatinib
  • 2.2.7 Others

3 Product Application Market

• 3.1 Overall Market Performance (Volume)
  • 3.1.1 Research Center
  • 3.1.2 Hospital
  • 3.1.3 Clinic

4 Manufacturers Profiles/Analysis

• 4.1 Ascenta Therapeutics, Inc.
  • 4.1.1 Ascenta Therapeutics, Inc. Profiles
  • 4.1.2 Ascenta Therapeutics, Inc. Product Information
  • 4.1.3 Ascenta Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Business Performance
  • 4.1.4 Ascenta Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Business Development and Market Status
• 4.2 AstraZeneca Plc
  • 4.2.1 AstraZeneca Plc Profiles
  • 4.2.2 AstraZeneca Plc Product Information
  • 4.2.3 AstraZeneca Plc Squamous Non-Small Cell Lung Cancer Therapeutics Business Performance
  • 4.2.4 AstraZeneca Plc Squamous Non-Small Cell Lung Cancer Therapeutics Business Development and Market Status
• 4.3 AVEO Pharmaceuticals, Inc.
  • 4.3.1 AVEO Pharmaceuticals, Inc. Profiles
  • 4.3.2 AVEO Pharmaceuticals, Inc. Product Information
  • 4.3.3 AVEO Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Business Performance
  • 4.3.4 AVEO Pharmaceuticals, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Business Development and Market Status
• 4.4 Bayer AG
  • 4.4.1 Bayer AG Profiles
  • 4.4.2 Bayer AG Product Information
  • 4.4.3 Bayer AG Squamous Non-Small Cell Lung Cancer Therapeutics Business Performance
  • 4.4.4 Bayer AG Squamous Non-Small Cell Lung Cancer Therapeutics Business Development and Market Status
• 4.5 BIND Therapeutics, Inc.
  • 4.5.1 BIND Therapeutics, Inc. Profiles
  • 4.5.2 BIND Therapeutics, Inc. Product Information
  • 4.5.3 BIND Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Business Performance
  • 4.5.4 BIND Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Business Development and Market Status
• 4.6 Boehringer Ingelheim GmbH
  • 4.6.1 Boehringer Ingelheim GmbH Profiles
  • 4.6.2 Boehringer Ingelheim GmbH Product Information
  • 4.6.3 Boehringer Ingelheim GmbH Squamous Non-Small Cell Lung Cancer Therapeutics Business Performance
  • 4.6.4 Boehringer Ingelheim GmbH Squamous Non-Small Cell Lung Cancer Therapeutics Business Development and Market Status
• 4.7 Bristol-Myers Squibb Company
  • 4.7.1 Bristol-Myers Squibb Company Profiles
  • 4.7.2 Bristol-Myers Squibb Company Product Information
  • 4.7.3 Bristol-Myers Squibb Company Squamous Non-Small Cell Lung Cancer Therapeutics Business Performance
  • 4.7.4 Bristol-Myers Squibb Company Squamous Non-Small Cell Lung Cancer Therapeutics Business Development and Market Status
• 4.8 Eli Lilly and Company
  • 4.8.1 Eli Lilly and Company Profiles
  • 4.8.2 Eli Lilly and Company Product Information
  • 4.8.3 Eli Lilly and Company Squamous Non-Small Cell Lung Cancer Therapeutics Business Performance
  • 4.8.4 Eli Lilly and Company Squamous Non-Small Cell Lung Cancer Therapeutics Business Development and Market Status
• 4.9 F. Hoffmann-La Roche Ltd.
  • 4.9.1 F. Hoffmann-La Roche Ltd. Profiles
  • 4.9.2 F. Hoffmann-La Roche Ltd. Product Information
  • 4.9.3 F. Hoffmann-La Roche Ltd. Squamous Non-Small Cell Lung Cancer Therapeutics Business Performance
  • 4.9.4 F. Hoffmann-La Roche Ltd. Squamous Non-Small Cell Lung Cancer Therapeutics Business Development and Market Status
• 4.10 Five Prime Therapeutics, Inc.
  • 4.10.1 Five Prime Therapeutics, Inc. Profiles
  • 4.10.2 Five Prime Therapeutics, Inc. Product Information
  • 4.10.3 Five Prime Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Business Performance
  • 4.10.4 Five Prime Therapeutics, Inc. Squamous Non-Small Cell Lung Cancer Therapeutics Business Development and Market Status
• 4.11 Genentech, Inc.
• 4.12 Incyte Corporation
• 4.13 Johnson & Johnson
• 4.14 MacroGenics, Inc.
• 4.15 Novartis AG
• 4.16 Oncogenex Pharmaceuticals, Inc.
• 4.17 PsiOxus Therapeutics Limited

5 Market Performance for Manufacturers

• 5.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales (K Units) and Market Share by Manufacturers 2014-2019
• 5.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (M USD) and Market Share by Manufacturers 2014-2019
• 5.3 Global Squamous Non-Small Cell Lung Cancer Therapeutics Price (USD/Unit) of Manufacturers 2014-2019
• 5.4 Global Squamous Non-Small Cell Lung Cancer Therapeutics Gross Margin of Manufacturers 2014-2019
• 5.5 Market Concentration

6 Regions Market Performance for Manufacturers

• 6.1 China Market Performance for Manufacturers
  • 6.1.1 China Squamous Non-Small Cell Lung Cancer Therapeutics Sales (K Units) and Share of Manufacturers 2014-2019
  • 6.1.2 China Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (M USD) and Share of Manufacturers 2014-2019
  • 6.1.3 China Squamous Non-Small Cell Lung Cancer Therapeutics Price (USD/Unit) of Manufacturers 2014-2019
  • 6.1.4 China Squamous Non-Small Cell Lung Cancer Therapeutics Gross Margin of Manufacturers 2014-2019
  • 6.1.5 Market Concentration
• 6.2 USA Market Performance for Manufacturers
  • 6.2.1 USA Squamous Non-Small Cell Lung Cancer Therapeutics Sales (K Units) and Share of Manufacturers 2014-2019
  • 6.2.2 USA Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (M USD) and Share of Manufacturers 2014-2019
  • 6.2.3 USA Squamous Non-Small Cell Lung Cancer Therapeutics Price (USD/Unit) of Manufacturers 2014-2019
  • 6.2.4 USA Squamous Non-Small Cell Lung Cancer Therapeutics Gross Margin of Manufacturers 2014-2019
  • 6.2.5 Market Concentration
• 6.3 Europe Market Performance for Manufacturers
  • 6.3.1 Europe Squamous Non-Small Cell Lung Cancer Therapeutics Sales (K Units) and Share of Manufacturers 2014-2019
  • 6.3.2 Europe Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (M USD) and Share of Manufacturers 2014-2019
  • 6.3.3 Europe Squamous Non-Small Cell Lung Cancer Therapeutics Price (USD/Unit) of Manufacturers 2014-2019
  • 6.3.4 Europe Squamous Non-Small Cell Lung Cancer Therapeutics Gross Margin of Manufacturers 2014-2019
  • 6.3.5 Market Concentration
• 6.4 Japan Market Performance for Manufacturers
  • 6.4.1 Japan Squamous Non-Small Cell Lung Cancer Therapeutics Sales (K Units) and Share of Manufacturers 2014-2019
  • 6.4.2 Japan Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (M USD) and Share of Manufacturers 2014-2019
  • 6.4.3 Japan Squamous Non-Small Cell Lung Cancer Therapeutics Price (USD/Unit) of Manufacturers 2014-2019
  • 6.4.4 Japan Squamous Non-Small Cell Lung Cancer Therapeutics Gross Margin of Manufacturers 2014-2019
  • 6.4.5 Market Concentration
• 6.5 Korea Market Performance for Manufacturers
  • 6.5.1 Korea Squamous Non-Small Cell Lung Cancer Therapeutics Sales (K Units) and Share of Manufacturers 2014-2019
  • 6.5.2 Korea Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (M USD) and Share of Manufacturers 2014-2019
  • 6.5.3 Korea Squamous Non-Small Cell Lung Cancer Therapeutics Price (USD/Unit) of Manufacturers 2014-2019
  • 6.5.4 Korea Squamous Non-Small Cell Lung Cancer Therapeutics Gross Margin of Manufacturers 2014-2019
  • 6.5.5 Market Concentration
• 6.6 India Market Performance for Manufacturers
  • 6.6.1 India Squamous Non-Small Cell Lung Cancer Therapeutics Sales (K Units) and Share of Manufacturers 2014-2019
  • 6.6.2 India Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (M USD) and Share of Manufacturers 2014-2019
  • 6.6.3 India Squamous Non-Small Cell Lung Cancer Therapeutics Price (USD/Unit) of Manufacturers 2014-2019
  • 6.6.4 India Squamous Non-Small Cell Lung Cancer Therapeutics Gross Margin of Manufacturers 2014-2019
  • 6.6.5 Market Concentration
• 6.7 Southeast Asia Market Performance for Manufacturers
  • 6.7.1 Southeast Asia Squamous Non-Small Cell Lung Cancer Therapeutics Sales (K Units) and Share of Manufacturers 2014-2019
  • 6.7.2 Southeast Asia Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (M USD) and Share of Manufacturers 2014-2019
  • 6.7.3 Southeast Asia Squamous Non-Small Cell Lung Cancer Therapeutics Price (USD/Unit) of Manufacturers 2014-2019
  • 6.7.4 Southeast Asia Squamous Non-Small Cell Lung Cancer Therapeutics Gross Margin of Manufacturers 2014-2019
  • 6.7.5 Market Concentration
• 6.8 South America Market Performance for Manufacturers
  • 6.8.1 South America Squamous Non-Small Cell Lung Cancer Therapeutics Sales (K Units) and Share of Manufacturers 2014-2019
  • 6.8.2 South America Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (M USD) and Share of Manufacturers 2014-2019
  • 6.8.3 South America Squamous Non-Small Cell Lung Cancer Therapeutics Price (USD/Unit) of Manufacturers 2014-2019
  • 6.8.4 South America Squamous Non-Small Cell Lung Cancer Therapeutics Gross Margin of Manufacturers 2014-2019
  • 6.8.5 Market Concentration

7 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Performance (Sales Point)

• 7.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales (K Units) and Market Share by Regions 2014-2019
• 7.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue (M USD) and Market Share by Regions 2014-2019
• 7.3 Global Squamous Non-Small Cell Lung Cancer Therapeutics Price (USD/Unit) by Regions 2014-2019
• 7.4 Global Squamous Non-Small Cell Lung Cancer Therapeutics Gross Margin by Regions 2014-2019

8 Development Trend for Regions (Sales Point)

• 8.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales and Growth, Sales Value and Growth Rate 2014-2019
• 8.2 China Squamous Non-Small Cell Lung Cancer Therapeutics Sales and Growth, Sales Value and Growth Rate 2014-2019
• 8.3 USA Squamous Non-Small Cell Lung Cancer Therapeutics Sales and Growth, Sales Value and Growth Rate2014-2019
• 8.4 Europe Squamous Non-Small Cell Lung Cancer Therapeutics Sales and Growth, Sales Value and Growth Rate 2014-2019
• 8.5 Japan Squamous Non-Small Cell Lung Cancer Therapeutics Sales and Growth, Sales Value and Growth Rate 2014-2019
• 8.6 Korea Squamous Non-Small Cell Lung Cancer Therapeutics Sales and Growth, Sales Value and Growth Rate 2014-2019
• 8.7 India Squamous Non-Small Cell Lung Cancer Therapeutics Sales and Growth, Sales Value and Growth Rate 2014-2019
• 8.8 Southeast Asia Squamous Non-Small Cell Lung Cancer Therapeutics Sales and Growth, Sales Value and Growth Rate 2014-2019
• 8.8 Southeast Asia Squamous Non-Small Cell Lung Cancer Therapeutics Sales and Growth, Sales Value and Growth Rate 2014-2019

9 Upstream Source, Technology and Cost

• 9.1 Upstream Source
• 9.2 Technology
• 9.3 Cost

10 Channel Analysis

• 10.1 Market Channel
• 10.2 Distributors

11 Consumer Analysis

• 11.1 Research Center Industry
• 11.2 Hospital Industry
• 11.3 Clinic Industry

12 Market Forecast 2020-2025

• 12.1 Sales (K Units), Revenue (M USD), Market Share and Growth Rate 2020-2025
  • 12.1.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales (K Units), Revenue (M USD) and Market Share by Regions 2020-2025
  • 12.1.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales (K Units) and Growth Rate 2020-2025
  • 12.1.3 China Squamous Non-Small Cell Lung Cancer Therapeutics Sales (K Units), Revenue (M USD) and Growth Rate 2020-2025
  • 12.1.4 USA Squamous Non-Small Cell Lung Cancer Therapeutics Sales (K Units), Revenue (M USD) and Growth Rate 2020-2025
  • 12.1.5 Europe Squamous Non-Small Cell Lung Cancer Therapeutics Sales (K Units), Revenue (M USD) and Growth Rate 2020-2025
  • 12.1.6 Japan Squamous Non-Small Cell Lung Cancer Therapeutics Sales (K Units), Revenue (M USD) and Growth Rate 2020-2025
  • 12.1.7 Korea Squamous Non-Small Cell Lung Cancer Therapeutics Sales (K Units), Revenue (M USD) and Growth Rate 2020-2025
  • 12.1.8 India Squamous Non-Small Cell Lung Cancer Therapeutics Sales (K Units), Revenue (M USD) and Growth Rate 2020-2025
  • 12.1.9 Southeast Asia Squamous Non-Small Cell Lung Cancer Therapeutics Sales (K Units), Revenue (M USD) and Growth Rate 2020-2025
  • 12.1.10 South America Squamous Non-Small Cell Lung Cancer Therapeutics Sales (K Units), Revenue (M USD) and Growth Rate 2020-2025
• 12.2 Sales (K Units), Revenue (M USD) Forecast by Types 2020-2025
  • 12.2.1 Overall Market Performance
  • 12.2.2 BMS-906024
  • 12.2.3 Buparlisib Hydrochloride
  • 12.2.4 FP-1039
  • 12.2.5 Ipilimumab
  • 12.2.6 JNJ-42756493
  • 12.2.7 Lenvatinib
  • 12.2.8 Others
• 12.3 Sales (K Units) Forecast by Application 2020-2025
  • 12.3.1 Overall Market Performance
  • 12.3.2 Research Center
  • 12.3.3 Hospital
  • 12.3.4 Clinic
• 12.4 Price (USD/Unit) and Gross Profit
  • 12.4.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Price (USD/Unit) Trend 2020-2025
  • 12.4.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Gross Profit Trend 2020-2025

13 Conclusion